Baiyong Li

2.7k total citations · 1 hit paper
66 papers, 1.5k citations indexed

About

Baiyong Li is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Baiyong Li has authored 66 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 17 papers in Radiology, Nuclear Medicine and Imaging and 17 papers in Immunology. Recurrent topics in Baiyong Li's work include Cancer Immunotherapy and Biomarkers (31 papers), Monoclonal and Polyclonal Antibodies Research (16 papers) and Peptidase Inhibition and Analysis (10 papers). Baiyong Li is often cited by papers focused on Cancer Immunotherapy and Biomarkers (31 papers), Monoclonal and Polyclonal Antibodies Research (16 papers) and Peptidase Inhibition and Analysis (10 papers). Baiyong Li collaborates with scholars based in China, Australia and United States. Baiyong Li's co-authors include Richard A. Flavell, Hong Yu, Roger J. Davis, Wei-ping Zheng, Zhongmin Maxwell Wang, Binfeng Lu, Tingting Zhong, David Leitenberg, Yu Xia and Judy Pawling and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Baiyong Li

64 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity

2023 100 citations Tingting Zhong, Zhongmin Maxwell Wang et al. profile →

Peers

Baiyong Li

IMMUN

ONCOL

PRM

RNMI

Sumita Trivedi United States

Enrico Tiacci Italy

Sabine Cerny‐Reiterer Austria

Eva M. Garrido‐Martín Spain

Philippe Quittet France

Laura V. Doyle United States

Michael Hundemer Germany

Keiko Okuda Japan

Sandra Coral Italy

Francesca Colizzi Italy

Sumita Trivedi United States

Baiyong Li

583 ×0.8

IMMUN

843 ×1.3

ONCOL

417 ×0.8

289 ×1.7

PRM

70 ×0.5

RNMI

Citations per year, relative to Baiyong Li Baiyong Li (= 1×) peers Sumita Trivedi

Countries citing papers authored by Baiyong Li

Since Specialization

Citations

This map shows the geographic impact of Baiyong Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Baiyong Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Baiyong Li more than expected).

Fields of papers citing papers by Baiyong Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Baiyong Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Baiyong Li. The network helps show where Baiyong Li may publish in the future.

Co-authorship network of co-authors of Baiyong Li

This figure shows the co-authorship network connecting the top 25 collaborators of Baiyong Li. A scholar is included among the top collaborators of Baiyong Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Baiyong Li. Baiyong Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Li, Wenfeng Fang, Yu Zhao, et al.. (2025). 1348 Final overall survival analysis of HARMONi-A study comparing ivonescimab plus chemotherapy to chemotherapy alone in patients with EGFR ⁺ NSCLC progressed on EGFR-TKI treatment. A1592–A1592.

Liu, Song, Ziqing Zeng, Zilei Wang, et al.. (2024). Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice. Biomedicine & Pharmacotherapy. 175. 116669–116669. 6 indexed citations

Chen, Qiuyan, Shanshan Guo, Ying Luo, et al.. (2024). Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study. Oral Oncology. 151. 106723–106723. 11 indexed citations

Lou, Hanmei, Hongbing Cai, Xin Huang, et al.. (2024). Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study. Clinical Cancer Research. 30(8). 1501–1508. 31 indexed citations

Zhong, Tingting, Lingzhi Zhang, Wenrong Liu, et al.. (2024). Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effects. iScience. 28(3). 111722–111722. 6 indexed citations

Wang, Jianghua, Xiaoting Li, Jayesh Desai, et al.. (2024). CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumors. Cancer Immunology Immunotherapy. 73(2). 36–36. 7 indexed citations

Zhao, Yuanyuan, Yuxiang Ma, Yun Fan, et al.. (2023). A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non–small-cell lung cancer (AK104-202 study). Lung Cancer. 184. 107355–107355. 37 indexed citations

Frentzas, Sophia, Hui Gan, Rasha Cosman, et al.. (2023). A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors. Cell Reports Medicine. 4(11). 101242–101242. 22 indexed citations

Qiao, Qian, Chun Han, Sisi Ye, et al.. (2023). The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial. Frontiers in Immunology. 14. 1238667–1238667. 30 indexed citations

10.

Li, Baiyong, et al.. (2022). Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed. Biomarker Research. 10(1). 20–20. 54 indexed citations

11.

Zheng, Yulong, Anna Rachelle Mislang, Jermaine Coward, et al.. (2022). Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers. Cancer Immunology Immunotherapy. 71(10). 2371–2379. 14 indexed citations

12.

Li, Qian, Ju Qiao, Hongzhong Jin, et al.. (2022). Population pharmacokinetic/pharmacodynamic analysis of AK111, an IL-17A monoclonal antibody, in subjects with moderate-to-severe plaque psoriasis. Frontiers in Pharmacology. 13. 966176–966176. 1 indexed citations

13.

Markman, Ben, Ben Tran, Hui Gan, et al.. (2019). A Phase 1 study of AK104, a tetrameric bispecific antibody that targets PD-1 and CTLA-4 in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 7. 3 indexed citations

14.

Fisher, Timothy S., Paul D. Lira, Jeffrey L. Stock, et al.. (2009). Analysis of the role of the HIF hydroxylase family members in erythropoiesis. Biochemical and Biophysical Research Communications. 388(4). 683–688. 6 indexed citations

15.

Chevalier, Éric, Jeff Stock, Timothy S. Fisher, et al.. (2005). Cutting Edge: Chemoattractant Receptor-Homologous Molecule Expressed on TH2 Cells Plays a Restricting Role on IL-5 Production and Eosinophil Recruitment. The Journal of Immunology. 175(4). 2056–2060. 69 indexed citations

16.

Fisher, Timothy S., et al.. (2005). Analysis of ARD1 Function in Hypoxia Response Using Retroviral RNA Interference. Journal of Biological Chemistry. 280(18). 17749–17757. 79 indexed citations

17.

Zheng, Wei-ping, Qian Zhao, Xinyan Zhao, et al.. (2004). Up-Regulation of Hlx in Immature Th Cells Induces IFN-γ Expression. The Journal of Immunology. 172(1). 114–122. 43 indexed citations

18.

Morgan, Rodney, et al.. (2004). N -Acetylglucosaminyltransferase V (Mgat5)-Mediated N -Glycosylation Negatively Regulates Th1 Cytokine Production by T Cells. The Journal of Immunology. 173(12). 7200–7208. 128 indexed citations

19.

Lu, Binfeng, Hong Yu, Baiyong Li, et al.. (2001). GADD45γ Mediates the Activation of the p38 and JNK MAP Kinase Pathways and Cytokine Production in Effector TH1 Cells. Immunity. 14(5). 583–590. 149 indexed citations

20.

Na, Songqing, Baiyong Li, Iqbal S. Grewal, et al.. (1999). Expression of activated CDC42 induces T cell apoptosis in thymus and peripheral lymph organs via different pathways. Oncogene. 18(56). 7966–7974. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact